Literature DB >> 18055474

Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.

M Hegen1, J C Keith, M Collins, C L Nickerson-Nutter.   

Abstract

Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA. However, the question of which animal model is most predictive of therapeutic efficacy in human RA commonly arises in data evaluation. A retrospective review of the animal models used to evaluate approved, pending RA therapies, and compounds that were discontinued during phase II or III clinical trials found that the three most commonly used models were adjuvant-induced arthritis (AIA) in rats and collagen-induced arthritis (CIA) in rats and mice. Limited data were found for more recently developed genetically modified animal models. Examination of the efficacy of various compounds in these animal models revealed that a compound's therapeutic efficacy, rather than prophylactic efficacy, in AIA and CIA models was more predictive of clinical efficacy in human RA than data from either model alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055474     DOI: 10.1136/ard.2007.076430

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  92 in total

1.  Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.

Authors:  Dongyang Liu; Hoi-Kei Lon; Debra C Dubois; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-16       Impact factor: 2.745

2.  The as-yet unfulfilled promise of p38 MAPK inhibitors.

Authors:  Susan E Sweeney
Journal:  Nat Rev Rheumatol       Date:  2009-09       Impact factor: 20.543

Review 3.  The multiple facets of glucocorticoid action in rheumatoid arthritis.

Authors:  Ulrike Baschant; Nancy E Lane; Jan Tuckermann
Journal:  Nat Rev Rheumatol       Date:  2012-10-09       Impact factor: 20.543

4.  Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats.

Authors:  Dawei Song; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2018-09-06       Impact factor: 4.200

5.  Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines.

Authors:  E Aizman; E Blacher; O Ben-Moshe; T Kogan; Y Kloog; A Mor
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

6.  Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.

Authors:  Dong-Yang Liu; Hoi-Kei Lon; Yan-Lin Wang; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2013-04-07       Impact factor: 1.627

7.  Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes.

Authors:  Sanna Rosengren; Maripat Corr; David L Boyle
Journal:  Arthritis Res Ther       Date:  2010-04-09       Impact factor: 5.156

8.  The choice of adjuvant determines the cytokine profile of T cells in proteoglycan-induced arthritis but does not influence disease severity.

Authors:  Jeroen N Stoop; Christopher A Tibbitt; Willem van Eden; John H Robinson; Catharien M U Hilkens
Journal:  Immunology       Date:  2013-01       Impact factor: 7.397

9.  Locomotion and muscle mass measures in a murine model of collagen-induced arthritis.

Authors:  Anita Hartog; Judith Hulsman; Johan Garssen
Journal:  BMC Musculoskelet Disord       Date:  2009-06-03       Impact factor: 2.362

10.  Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.

Authors:  Astrid Jüngel; Caroline Ospelt; Mark Lesch; Melissa Thiel; Teresa Sunyer; Olivier Schorr; Beat A Michel; Renate E Gay; Christoph Kolling; Craig Flory; Steffen Gay; Michel Neidhart
Journal:  Ann Rheum Dis       Date:  2009-06-03       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.